Genomma Lab Internacional, S.A.B. de C.V. EBIT

The latest EBIT for GNMLF is $4.2B as of September 2026. That compares with $3.4B in the prior-year period — up 22.0% year over year. That is below the sector sector average of $2.5T. Investors often review this figure alongside Genomma Lab Internacional, S.A.B. de C.V.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, GNMLF's EBIT moved from $3.4B to $4.2B — a 22.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Genomma Lab Internacional, S.A.B. de C.V.'s operating scale or balance-sheet position.

Against its sector companies, GNMLF currently prints $4.2B for EBIT, while the sector average sits near $2.5T. That is roughly 99.8% below the sector mean. Large gaps often invite a closer look at Genomma Lab Internacional, S.A.B. de C.V.'s growth, margins, and balance sheet.

A EBIT figure of $4.2B for GNMLF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.5T. Explore the charts below for those layers of context.

After noting GNMLF's EBIT ($4.2B), review year-over-year change from $3.4B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.